Related Experiment Video
Updated: Apr 27, 2026

Functional Human Liver Preservation and Recovery by Means of Subnormothermic Machine Perfusion
Published on: April 27, 2015
A single-center experience of non-bioartificial liver support systems among Chinese patients with liver failure
Qi Xia1, Xiahong Dai, Jianrong Huang
1*Qi Xia and Xiahong Dai contributed equally to this work.
Introduction:
Liver failure is one of the most deadly, prevalent, and costly diseases worldwide. Non-bioartificial liver support systems (NBALs) have been shown to be effective in improving the clinical symptoms and laboratory parameters of patients with liver failure. The main aim of this large case series analysis was to investigate the status of NBALs and their effectiveness in improving survival in liver-failure patients.
Methods:
In this retrospective study, 460 patients with liver failure who received NBAL treatment in addition to conventional medications were compared with 422 patients who were treated with conventional medications alone. Kaplan-Meier and life table analyses were used to estimate survival rates.
Results:
Clinical outcomes were improved after NBAL treatment. The 30-day survival rates of subacute liver failure (SALF) patients were 63% among those who received NBALs and 21% among those who did not receive NBALs (p < 0.01). Similarly, the 30-day survival rate of acute-on-chronic liver failure (ACLF) patients who received NBALs was 47%, significantly higher than that of the non-NBAL patients (p < 0.05). The survival rates of ACLF patients with low Model for End-Stage Liver Disease (MELD) scores (MELD ≤ 20) were 64% and 40% among whom received NBALs and those who did not, respectively (p < 0.01).
Conclusions:
NBAL treatment is helpful to improve the survival of patients with ALF, SALF or ACLF. ACLF patients with lower MELD scores showed improved outcomes relative to those with higher MELD scores.
More Related Videos
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

